Current status of high dose progestin treatment in advanced breast cancer.
Progestins, especially high dose medroxyprogesterone acetate, are receiving renewed attention in treatment of advanced breast cancer. The trials reviewed here indicate that such regimens may be as effective as tamoxifen in postmenopausal unselected cases, and that they may be effective as second-line treatment in patients resistant to tamoxifen and/or to cytotoxic chemotherapy.
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000378:metabolism; D007273:Injections, Intramuscular; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D017258:Medroxyprogesterone Acetate; D011980:Receptors, Progesterone / Q000378:metabolism
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D011980:Receptors, Progesterone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone